Skip to main content

THE 3R LÄND Conference

Organoids, Organ-on-Chip, and In Silico Models have transformed biomedical and pharmaceutical research, marking a new era of experimentation. Organoids mimic the structure and function of organs, providing a physiologically human-relevant platform for disease study and drug testing. Organ-on-Chip systems replicate human organ microenvironments, offering dynamic conditions for drug assessment. In Silico Models, driven by computational simulations, expedite drug discovery by analyzing complex biological processes. These models contribute to accurate, efficient, and human-centered research, reducing reliance on animal testing and advancing biomedical and pharmaceutical sciences.

The 3R-Center Tübingen for In vitro Models and Alternatives to Animal Testing at the University of Tübingen and the NMI Natural and Medical Sciences Institute in Reutlingen is thrilled to host the first 3R LÄND Conference in the heart of the Länd, Tübingen, Germany. The conference unites academia, clinicians, industry representatives, regulatory agencies, and policymakers in the biomedical and pharmaceutical field. We invite all interested parties to join us on May 21-23, 2024, for a deep dive into the forefront of biomedical and pharmaceutical research. Engage in exciting keynote lectures, scientific presentations, poster sessions, and networking opportunities for interdisciplinary exchange.

Stay tuned for details and spread the word among your colleagues and students!

We look forward to meeting you in May 2024 in Tübingen!

Meet our generous Sponsors:

Venue

The Conference will take place at the Morgenstelle Auditorium Center of the University of Tübingen.

Auditorium Center
Auf der Morgenstelle 16
72076 Tübingen
Germany

Accessibility
The building is barrier-free and accessible at all levels.

Important Deadlines

  • Abstract Submission: Abstract Submission for oral presentation has closed on January 31st, 2024. Late-breaking abstract submission for posters continues to be open!
  • Registration: Registration is now open! Save yourself one of the limited tickets!

Updates & News

Stay up to date and find all relevant information on demand via the 3R-Centers Tübingen’s LinkedIn or the Twitter account!

Hotel Recommendations

Below you will find a list of hotels in the immediate vicinity of the venue:

Hotel & Website Address Distance to the venue
(by public transportation)
Hotel Krone Uhlandstrasse 1, 72072 Tübingen ~ 17 min
Hotel Alte Krone Kreuzstraße 21, 72074 Tübingen ~ 28 min
Hotel Ibis Style (room contingent available*) Friedrichstraße 20, 72072 Tübingen ~ 21 min
GZT Gästehaus (room contingent available*)
Hoppe-Seyler-Straße 6, 72076 Tübingen ~ 10 min
Hotel Metora Weizsäckerstraße 1, 72074 Tübingen ~ 24 min
Hotel Barbarina Wilhelmstraße 94, 72074 Tübingen ~ 21 min
Hotel Domizil (room contingent available*) Wöhrdstrasse 5-9, 72072 Tübingen ~ 19 min
Hotel Katharina Garni Lessingweg 2 , 72076 Tübingen ~ 18 min
Hotel Restaurant „Kreuzberg” Vor dem Kreuzberg 23, 72070 Tübingen ~ 24 min
Hotel am Schloss Burgsteige 18, 72070 Tübingen ~ 24 min
Hotel Venezia Dieselstraße 2, 72074 Tübingen-Lustnau ~ 26 min
Hermann-Kurz-Str. 4, 72074 Tuebingen ~ 25 min

* To secure a room from the reserved hotel allocation, kindly make your reservations via email or by phone, referencing the retrieval code „The3RLänd„. Please note that the number of rooms available in the reserved contingent is limited, and reservations will be confirmed on a ‚first come, first served‘ basis.

Registration

Early Bird Ticket
EUR 200,-
Regular Ticket
EUR 250,-
Available from March 2nd, 2024 onwards

The payment process is carried out via Ventura Labs and takes place in the name and for the account of the Universitätsklinikum Tübingen A. d. oe. R. registered office Tübingen. All prices are VAT included. You will receive a VAT invoice during the process. VAT ID DE146889674

The Conference Ticket includes:
  • Access to all keynote lectures
  • Access to all scientific sessions
  • Access to all poster sessions
  • Access to all sponsor and exhibitor booths
  • Refreshments (daily) and catered lunches (Wed + Thu)
  • Admission to special events – Welcome Reception (Tue); and Conference Dinner (Wed)

Please Note:

Conference registrations are personal and binding. They are non-refundable and non-transferable to another individual, irrespective of non-attendance or any other reason.

Program at a Glance

Format

  • Opening Ceremony (Start: May 21st, 1 PM) and Closing Ceremony (End: May 23rd, 4:30 PM)
  • Keynote Lectures and Expert Presentations
  • Oral Presentations meticulously selected from the submitted abstracts
  • Poster Presentations
  • Rapid-Fire Pitch Talks

Keynote lectures

  • Prof. Dr. Josef Penninger (Helmholtz Centre for Infection Research, DE): Human organoids for infection research
  • Prof. Dr. Daniela Salvatori (Utrecht University, NL): The power of education for the transition to animal-free innovation: from theory to practice
  • Prof. Dr. Marcel Leist (Konstanz University, DE): Development of non-animal methods for neurodegeneration research and neurotoxicity assessment
  • Prof. Dr. Simone Mayer (Karlsruhe Institute of Technology & Hertie Institute for Clinical Brain Research, DE): Human brain organoids as models of rare neurological disorders as a stepping stone towards personalized medicine
  • Prof. Dr. Peter Loskill (Eberhard Karls University Tübingen, DE): Recapitulating Complex Tissues using Organ-on-chip and Organoid Technologies

Sessions

  • Innovation in Organ-on-Chip Models
    • Chair: Julia Rogal (Karolinska Institutet, Stockholm, SE)
    • Opening Speaker: Stefan Krauss (Oslo University, NO): Promises and challenges of microphysiological liver models
  • Innovation in Organoid Models
    • Chair: Deborah Kronenberg-Versteeg (DZNE Tübingen, DE)
    • Opening Speaker: Stefan Liebau (Eberhard Karls University Tübingen, DE): Getting closer to a glance back from the dish – next generation retinal organoids
  • Innovation in In Silico Models
    • Opening Speaker: Oliver Röhrle (University of Stuttgart, DE): In silico modelling: chances and challenges
  • Application of NAMs for Rare Diseases and Personalized Medicine
    • Chair: Julia Marzi (NMI Natural and Medical Sciences Institute, Reutlingen, DE)
    • Opening Speaker: Marianne Carlon (KU Leuven, BE): Implementing patient-derived in vitro models for translational testing of gene editing therapies for cystic fibrosis
  • Training and Education for NAMs
    • Chair: Silke Keller (3R-Center Tübingen, DE)
    • Opening Speaker: Lucia Selfa Aspiroz (JRC EURL ECVAM, Ispra, IT): Empowering the scientists of today and tomorrow: EC resources on 3Rs for students and researchers
  • Application of NAMs for Environmental, Food and Chemical Toxicology
    • Chair: Madalena Cipriano (Eberhard Karls University Tübingen, DE)
    • Opening Speaker: Karilyn E. Sant (San Diego State University, CA, USA): Embryonic and aquatic toxicity of common environmental pollutants: the case for tire tread particles and emerging coastal mixtures
  • NAM-based Basic Biomedical Research
    • Chair: Monilola Olayioye (University of Stuttgart, DE)
    • Opening Speaker: Alexander Mosig (Jena University, DE): Exploring human infections: Studying immune response and host-pathogen interactions using organ-on-chip technology
  • Use of NAMs in Industrial Research
    • Chairs: Mario Beilmann (Boehringer-Ingelheim, DE) & Stefan Kustermann (Roche, CH)
    • Speakers: 
      • Mario Beilmann (Boehringer-Ingelheim, DE): MPS for mechanistic toxicity investigations: example drug-induced liver injury (DILI)
      • Gautier Roussignol (Sanofi, FR): Human microbrain 3D model for non-clinical neuronal safety evaluation at early phase of drug development
      • Diana Karwelat (Bayer, DE): Advanced cellular models at Bayer (Pharmaceuticals) – Use cases and current challenges
      • Terry van Vleet (Abbvie, USA): Current opportunities and remaining challenges for NAMs impact in pharmaceutical safety assessment
      • Adrian Roth (Roche, CH): Patient-derived human tissue models supporting precision medicine in clinical drug development
      • Rhiannon N. Hardwick (Bristol Myers Squibb, USA): Onboarding and Context of Use Qualification Considerations for GI and Liver CIVM/MPS Applications in Discovery Toxicology

Keynote Speaker

Prof. Dr. Josef Penninger

Josef Penninger born in Gurten, Austria, is since July 1, 2023 the Scientific Director of the Helmholtz Centre for Infection Research in Germany. At the same time, he was appointed part-time Professor for Precision Medicine at the Medical University of Vienna. Josef Penninger studied medicine at the University of Innsbruck. From 1990 to 1994 he worked as post-doctoral fellow at the Ontario Cancer Institute, thereafter until 2002 at the Department of Immunology and Medical Biophysics at the University of Toronto. As Principal Investigator at Amgen, his independent lab contributed to the development of the antibody Denosumab for bone loss and found the first connection for RANKL to mammary gland development in pregnancy and breast cancer. In 2002, he moved to Vienna, to start and develop the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, which has become one of the prime research centers in the world. From the end of 2018 to June 2023 Josef Penninger returned to Canada and was the Director of the Life Sciences Institute at the University of British Columbia. Dr. Penninger created a similar environment at the LSI that nurtured and trained the best and brightest young minds of UBC scholars. His major accomplishments include pioneering insights into the molecular basis of osteoporosis and breast cancer and demonstrating a critical role for ACE2 as the cellular receptor for SARS Coronavirus infections and linking ACE2 to lung failure in such infections.

Prof. Dr. Daniela Salvatori

Daniela Salvatori works as Professor of Comparative Anatomy and Physiology at the Veterinary Faculty, in Utrecht, The Netherlands.
She is a veterinarian and a European Certified Veterinary Pathologist. She leads from 2019 the Utrecht Transition Program to Animal-free Innovations, an interdisciplinary group focused on innovation of research and education without use of laboratory animals.
Her research studies mechanisms of tumorigenesis of human and animal stem cells, and works on the characterization and validation of in vitro models for studying human and animal diseases. She works on evidence-based approaches for introduction of animal-free educational methods, in particular on plastination and virtual reality.

She has recently worked on the vision document focused on the use of fewer laboratory animals in higher education published by the Universities of the Netherlands and the Dutch Medical Hospital.

Her work focuses on animal-free innovations in life science education and on the importance of education as catalyst for acceptance of animal-free new approach methodologies. Her lecture will focus on these two aspects.

Prof. Dr. Simone Mayer

Simone Mayer is originally from Baden-Württemberg. She obtained her BA hons degree in Natural Sciences at the University of Cambridge (UK) and a MSc and PhD from the Georg August University Göttingen, International Max Planck Research School for Molecular Biology focusing on synaptic neurobiology. She did her postdoctoral work in the lab of Arnold Kriegstein at the Broad Stem Cell Center of the University of California, San Francisco funded by the European Molecular Biology Organization and the German Research Foundation (2015-2018) and developed a novel technique to perform multimodal single-cell analysis.

In 2018, she returned to Baden-Württemberg to set up her independent research group in „Molecular Brain Development“ at the Hertie Institute for Clinical Brain Research / University of Tübingen. During this time, she leveraged her expertise in human brain development and stem cell biology to establish several human brain organoid models of neurodegenerative and neurodevelopmental disorders. She has a strong focus on patient engagement, working very closely together with the patient organization PCH-Familie e.V. to reveal disease mechanisms underlying the rare genetic disorder pontocerebellar hypoplasia (PCH). Her work has been recognized by the Eva Luise Köher Research Award in 2023 and a Chan Zuckerberg Initiative Grant in 2022.

Since February 2024, Dr. Mayer holds the W3-professorship for Systemic Cellular Neurobiology at the Karlsruhe Institute of Technology (KIT).

Prof. Dr. Marcel Leist

Marcel Leist obtained an MSc in toxicology (Guildford 1989), and a PhD in pharmacology (Konstanz 1993). Since 2006, he has been head of the Department of In vitro Toxicology and Biomedicine at the University of Konstanz (inaugurated by the Doerenkamp-Zbinden Foundation), and director of the Center for Alternatives to Animal Testing in Europe (CAAT-Europe), a joint venture with Johns-Hopkins University. From 2000-2006, he worked as ‘Head of Department of Disease Biology’ on the discovery of neurology and psychiatry drugs in the Danish pharmaceutical company Lundbeck A/S. His research resulted in > 400 publications (cited over 35,000 times), and was awarded with many national and international research prizes. The current research addresses the question on how model data can be used for the prediction of the adverse effects of chemicals on the human population. While the current safety system world-wide is based on the use of experimental animals as model system, the research of Marcel has focused on new approaches to use alternative data sources. Steps towards this include (i) the development of non-animal new approach methods (NAM), (ii) the integration of multiple information layers from NAM in next generation risk assessment (NGRA), (iii) extrapolation of model data to complex real-life scenarios, and (iv) uncertainty analyses for the predictions. An example is the contribution to the GIVIMP guideline issued by the OECD or the developmental neurotoxicity in vitro test battery promoted by EFSA and the EPA.

Prof. Dr. Peter Loskill

Peter Loskill is Full Professor for Organ-on-Chip (OoC) Research at the Eberhard Karls University Tübingen (EKUT) and the NMI Natural and Medical Sciences Institute at the University of Tübingen in Reutlingen, and head of the 3R-Center Tübingen for In vitro Models and Alternatives to Animal Testing. Dr. Loskill graduated in 2012 from Saarland University with a PhD in Physics focusing on Biointerface Science. He then spent three years as postdoctoral fellow in the Healy lab at University of California at Berkeley developing human induced pluripotent stem cells (hiPSC)-based OoC models, funded by the NIH/NCATS TissueChip program and the German Science Foundation (DFG). In 2015, he was named as one of Technology Review’s “Innovators under 35 Germany” and awarded a Fraunhofer ATTRACT Grant, the highest funded German starting grant program, which enabled him to start an independent research group at Fraunhofer IGB Stuttgart. In 2021, he accepted a W3-professor position, heading the Department for Microphysiological Systems in the Faculty of Medicine at EKUT and NMI. From 2021 to 2023, he served as the Chair of the European Organ-on-Chip Society (EUROoCS) and, in 2023, he became part of the governing board of the International MPS Society (iMPSS). Dr. Loskill and his interdisciplinary µOrganoLab merge engineering, biology, physics, and medicine to generate next generation tissue models recapitulating complex human biology in vitro. His research focuses on i) development of tailored OoC platforms, ii) application of OoCs for pharmaceutical research, toxicological screening, and biomedical studies, as well as on iii) enabling technologies that support parallelization, automation, and ease of use.

Submit your late-breaking Abstract

Please note that late-breaking abstract submissions can only be accepted as posters.












    YesNo
    (Young investigators: undergraduate and graduate students, PhD candidates)


    Oral presentationPoster presentation


    Please use the provided template, and upload only one file in PDF format which is below 5 MB of file size. We cannot consider applications which are not complete.


    I have read the data protection regulations and agree to the data processing

    We will treat your personal data confidentially and in accordance with the statutory data protection regulations and the privacy policy. Your data will of course be treated confidentially. By checking the box, you declare that you are familiar with and agree to the privacy policy listed at: Data privacy

    Technical Requirements & Deadline

    • File Submission Guidelines:
      • Template: Please utilize the provided template for abstract preparation. Download the template, fill in your details, and save the document in PDF format. Upload the completed PDF using the form below.
      • Language and Word Limit: Abstracts must be in English and should not exceed 350 words (including references; excluding title and authors).
      • File Format and Size: Please upload a single PDF file with a file size not exceeding 5 MB. Incomplete applications cannot be considered.
      • Abstract Evaluation and Selection: All abstracts will be evaluated and selected for oral or poster presentation by the Program Committee
      • Author Information: Full first and last names of all authors; abbreviate middle names (e.g., Peter R. S. Parker); presenting author should be identified. Provide affiliations including institute/company, town, and country for each author. E-mail address of presenting author should be provided.
      • Additional Information in Abstract: Acknowledgements, disclaimers or funding information may be included at the end of the abstract.
    • Confidentiality Note:
      • Kindly refrain from including any confidential material in your abstracts. Note that all accepted abstracts will be freely accessible to all conference participants.
    • Presentation Selection:
      • Submitted abstracts will be considered for either oral presentation or inclusion in the interactive poster session.
    • Author Limitation:
      • Each presenting author is allowed to submit only one abstract.
    • Conference Registration Requirement:
      • It is mandatory for all presenters to be registered for the conference if their abstract is accepted.

    Template Download

    Click here to download the Template

    Deadline for Abstract Submission

    • The deadline for submitting abstracts is Wednesday, January, 31st, 2024

    Notice to Authors

    • Authors will be notified on the decision of the Program Committee by February, 14th, 2024

    Late-Breaking Abstracts

    • Late-breaking abstract submissions can only be accepted as posters

    Stay in Touch!

    Stay up to date! Check out Social Media (LinkedIn & Twitter/X) channels to not miss any news on the Annual 3R-Conference!

    THE 3R LÄND

    Annual Conference of the 3R-Network Baden-Württemberg

    You have questions on the „THE 3R LÄND Conference“?